Lexicon Pharmaceuticals | LXRX - Operating Profit


Lexicon Pharmaceuticals reported $-55.35M in Operating Profit for its fiscal quarter ending in June of 2024.





Operating Profit Change Date
Abbott USD 2.25B 73M Dec/2025
Acadia Pharmaceuticals USD 17.39M 18.36M Dec/2025
Agios Pharmaceuticals USD -121.58M 4.71M Dec/2025
Akebia Therapeutics USD 13.51M 27.82M Mar/2025
Alnylam Pharmaceuticals USD 29.4M 59.36M Dec/2025
AstraZeneca USD 2.97B 4.48B Dec/2025
BioMarin Pharmaceutical USD 198.39M 230.08M Dec/2025
Coherus Biosciences USD -45.43M 3.13M Mar/2025
Eli Lilly USD 8.99B 599.9M Dec/2025
Esperion Therapeutics USD -16.03M 18.6M Sep/2024
Halozyme Therapeutics USD -88.41M 306.33M Dec/2025
Illumina USD 256M 6M Dec/2025
Insmed USD -249.71M 11.64M Dec/2025
Ironwood Pharmaceuticals USD 33.22M 7.58M Dec/2024
J&J USD 5.59B 1.81B Dec/2025
Lexicon Pharmaceuticals USD -55.35M 10.02M Jun/2024
MacroGenics USD 18.64M 55.4M Sep/2025
MannKind USD -69.24M 28.19M Dec/2025
Merck USD 6.24B 318M Dec/2025
Moderna USD -857M 597M Dec/2025
Novartis USD 4.5B 363M Sep/2025
PTC Therapeutics USD -81.62M 85.11M Dec/2025
Puma Biotechnology USD 22.08M 24.26M Sep/2024
Sarepta Therapeutics USD -410.08M 347.2M Dec/2025
Thermo Fisher Scientific USD 2.3B 226M Dec/2025
Ultragenyx Pharmaceutical USD -114M 56.89M Dec/2025
United Therapeutics USD -14.6M 403.9M Dec/2025
Vanda Pharmaceuticals USD -40.66M 29.66M Dec/2024